Treatment
Patients were randomly assigned (1:1) to receive either NEPA or aprepitant‐based treatment, both in conjunction with DEX (12 mg) prior to chemotherapy on day 1. NEPA was administered as a single oral capsule (300 mg netupitant, 0.50 mg palonosetron) approximately 1 h prior to chemotherapy on day 1 only, while oral aprepitant (125 mg) was administered approximately 1 h prior to chemotherapy and also once daily (80 mg) on days 2 and 3. Per protocol, intravenous ondansetron (8 mg) was the 5‐HT